COMBINATION TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN PATIENTS WITH RAS PATHWAY MUTATIONS
Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. The methods further comprise administering a therapeutically effective amount of a hypomethylating agent. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a hypomethylating agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. A therapeutically effective amount of a hypomethylating agent is further administered according to the provided methods.
1 . A method for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising:
a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and
b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody.
2 . The method of claim 1 , further comprising administering a therapeutically effective amount of a hypomethylating agent for five to seven days starting on day one of administration of the anti-hGM-CSF antibody.
3 . The method of claim 2 , wherein the hypomethylating agent is selected from the group consisting of azacytidine, decitabine, and a combination of decitabine and cedazuridine.
4 . The method of claim 1 , wherein the anti-hGM-CSF antibody is lenzilumab.
5 . The method of claim 1 , wherein the anti-hGM-CSF antibody is selected from the group consisting of Namilumab, Otilimab, Gimsilumab, and TJM2 (TJ003234).
6 . The method of claim 2 , wherein the anti-hGM-CSF antibody is lenzilumab.
7 . The method of claim 2 , wherein the anti-hGM-CSF antibody is selected from the group consisting of consisting of Namilumab, Otilimab, Gimsilumab, and TJM2 (TJ003234).
8 . The method of claim 4 , wherein the anti-hGM-CSF antibody lenzilumab is administered on day one and day 15 of cycle 1 and on day one only for all subsequent cycles.
9 . The method of claim 8 , wherein the all subsequent cycles consist of a total of 24 cycles, and each cycle consists of 28 days.
10 . The method of claim 1 , wherein the subject has a RAS pathway mutation and a TET2 mutation identified in the tumor cells.
11 . The method of claim 1 , wherein the subject has a RAS pathway mutation and two TET2 mutation variants identified in the tumor cells.
12 . The method of claim 4 , wherein the anti-hGM-CSF antibody lenzilumab is administered intravenously (IV) at a dose of from 552 mg to 1656 mg, wherein the dose of 552 mg is administered over a 1 hour IV infusion and the dose of 1656 mg is administered over 2 hour(s) IV infusion.
13 . The method of claim 4 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 552 mg over a 1 hour IV infusion.
14 . The method of claim 3 , wherein the hypomethylating agent is administered subcutaneously at a dose of 75 mg/m 2 .
15 . The method of claim 2 , wherein the administration demonstrates a complete response (CR) plus partial response (PR) of 50-90% compared to complete response (CR) plus partial response (PR) of 10-17% achieved with sole administration of a hypomethylating agent.
16 . The method of claim 15 , wherein the response is a complete response or a partial response during 6 first cycles.
17 . The method of claim 15 , wherein the CR or PR result in improved survival and progression-free survival at two years after treatment compared to survival and progression-free survival at two years after administration of a hypomethylating agent alone.
18 . The method of claim 2 , wherein the administration demonstrates/achieves clinical benefit at any point during 24 cycles.
19 . The method of claim 18 , wherein the clinical benefit comprises impact on physical and functional capacity of the subject; social well-being of the subject, hematological and non-hematologic safety and combinations thereof.
20 . A method for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising:
a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and
b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody and a therapeutically effective amount of a hypomethylating agent.
21 . The method of claim 20 , wherein the hypomethylating agent is selected from the group consisting of azacytidine, decitabine, and a combination of decitabine and cedazuridine.
22 . The method of claim 20 , wherein the hypomethylating agent is administered for five to seven days starting on day one of administration of the anti-hGM-CSF antibody.
23 . The method of claim 20 , wherein the anti-hGM-CSF antibody is lenzilumab.
24 . The method of claim 20 , wherein the anti-hGM-CSF antibody is selected from the group consisting of Namilumab, Otilimab, Gimsilumab, and TJM2 (TJ003234).
25 . The method of claim 21 , wherein the anti-hGM-CSF antibody is lenzilumab.
26 . The method of claim 21 , wherein the anti-hGM-CSF antibody is selected from the group consisting of Namilumab, Otilimab, Gimsilumab, and TJM2 (TJ003234)
27 . The method of claim 23 , wherein the anti-hGM-CSF antibody lenzilumab is administered on day one and day 15 of cycle 1 and on day one only for all subsequent cycles.
28 . The method of claim 27 , wherein the all subsequent cycles consist of a total of 24 cycles, and each cycle consists of 28 days.
29 . The method of claim 20 , wherein the subject has a RAS pathway mutation and a TET2 mutation identified in the tumor cells.
30 . The method of claim 20 , wherein the subject has a RAS pathway mutation and two TET2 mutation variants are identified in the tumor cells.
31 . The method of claim 23 , wherein the anti-hGM-CSF antibody lenzilumab is administered intravenously (IV) at a dose of from 552 mg to 1656 mg, wherein the dose of 552 mg is administered over a 1 hour IV infusion and the dose of 1656 mg is administered over 2 hours IV infusion.
32 . The method of claim 23 , wherein the anti-hGM-CSF antibody lenzilumab is administered at a dose of 552 mg over a 1 hour IV infusion.
33 . The method of claim 21 , wherein the azacitidine, decitabine, or the combination of decitabine and cedazuridine is administered subcutaneously at a dose of 75 mg/m 2 .
34 . The method of claim 21 , wherein administration of the anti-hGM-CSF antibody lenzilumab and the hypomethylating agent demonstrates a complete response (CR) plus partial response (PR) of 50-90% compared to a CR+PR rate of 10-17% achieved with sole administration of a hypomethylating agent.
35 . The method of claim 34 , wherein the response is a complete response or a partial response during 6 first cycles.
36 . The method of claim 34 , wherein the CR or PR result in improved survival and progression-free survival at two years after treatment compared to survival and progression-free survival at two years after administration of a hypomethylating agent alone.
37 . The method of claim 21 , wherein the administration demonstrates/achieves clinical benefit at any point during 24 cycles.
38 . The method of claim 37 , wherein the clinical benefit comprises impact on physical and functional capacity of the subject; social well-being of the subject, hematological and non-hematologic safety and combinations thereof.
39 . The method of claim 19 , wherein the hematological safety comprises (a) a decrease in C-reactive protein (CRP) by at least 50% within six months of administering the therapeutically effective amount of the therapeutically effective amount of the anti-hGM-CSF antibody and the hypomethylating agent compared to baseline CRP prior to treatment, and (b) an improvement in hematological parameters.
40 . The method of claim 19 , wherein the hematological safety comprises (a) an improved bone marrow response of less than 5% blasts within 12 months or (b) a complete response in subjects having a medium increase in GM-CSF and pro-inflammatory cytokines found in an innate immune response and MI macrophage activation compared to levels of GM-CSF and pro-inflammatory cytokines and MI macrophage activation in healthy subjects within 12 months.
41 . The method of claim 19 , wherein the clinical benefit comprising impact on the physical capacity of the subject comprises a reduction in splenomegaly.
42 . The method of claim 19 , wherein the hematological safety comprises a decrease in a variant allele frequency (VAF) of at least one identified RAS-pathway mutation, wherein the RAS-pathway mutation is KRAs and/or CBL.
43 . The method of claim 38 , wherein the hematological safety comprises (a) a decrease in C-reactive protein (CRP) by at least 50% within six months of administering the therapeutically effective amount of the therapeutically effective amount of the anti-hGM-CSF antibody and the hypomethylating agent compared to baseline CRP prior to treatment, and (b) an improvement in hematological parameters.
44 . The method of claim 38 , wherein the hematological safety comprises (a) an improved bone marrow response of less than 5% blasts within 12 months or (b) a complete response in subjects having a medium increase in GM-CSF and pro-inflammatory cytokines found in an innate immune response and Ml macrophage activation compared to levels of GM-CSF and pro-inflammatory cytokines and M1 macrophage activation in healthy subjects within 12 months.
45 . The method of claim 38 , wherein the clinical benefit comprising impact on the physical capacity of the subject comprises a reduction in splenomegaly.
46 . The method of claim 38 , wherein the hematological safety comprises a decrease in a variant allele frequency (VAF) of at least one identified RAS-pathway mutation, wherein the RAS-pathway mutation is KRAs and/or CBL.
47 . The method of claim 2 , further comprising treating the subject with an allogeneic transplant.
48 . The method of claim 20 , further comprising treating the subject with an allogeneic transplant.